New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
06:06 EDTAGN, MNKDStocks with implied volatility below IV index mean; AGN MNKD
Stocks with implied volatility below IV index mean; Allergan (AGN) 32, MannKind (MNKD) 73 according to iVolatility.
News For AGN;MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
08:53 EDTMNKDNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
06:05 EDTMNKDStocks with implied volatility movement; MNKD MRVL
Subscribe for More Information
February 27, 2015
10:32 EDTMNKDOptions with decreasing implied volatility
Subscribe for More Information
08:34 EDTAGNAllergan says FDA approves Natrelle Inspira breast implants
Subscribe for More Information
February 25, 2015
05:52 EDTMNKDStocks with implied volatility movement; MNKD NE
Stocks with implied volatility movement; MannKind (MNKD) 79, Noble Corp. (NE) 52 according to iVolatility.
February 24, 2015
16:48 EDTMNKDMannKind reports Q4 EPS (9c), consensus (9c)
Subscribe for More Information
February 23, 2015
15:06 EDTMNKDMannKind volatility increases into Q4 and outlook
MannKind February weekly call option implied volatility is at 103, March is at 63, April is at 60. May is at 55; compared to its 26-week average of 70 according to Track Data, suggests large near term price movement into the expected release into the expected release of Q4 result on February 24.
February 20, 2015
07:08 EDTAGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
07:40 EDTAGNActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
February 18, 2015
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2
February 17, 2015
18:06 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:18 EDTAGNPershing Square gives quarterly update on stakes
NEW STAKES: Restaurant Brands International (QSR). INCREASED STAKES: Zoetis (ZTS), and Platform Specialty Products (PAH). DECREASED STAKES: Allergan (AGN). LIQUIDATED STAKES: None.
17:02 EDTAGNSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
13:52 EDTAGNEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use